Erectile Dysfunction News and Research RSS Feed - Erectile Dysfunction News and Research

Erectile Dysfunction (ED) is defined as the consistent inability to attain and maintain an erection sufficient for satisfactory sexual intercourse. ED affects up to 30 million men in the United States, with 52% of men between the ages of 40 and 70 reporting difficulty with erectile function. By the year 2025, it is estimated that 322 million men worldwide will suffer from some degree of sexual dysfunction.
Can-Fite BioPharma announces Q2 financial results for 2015, updates drug development programs

Can-Fite BioPharma announces Q2 financial results for 2015, updates drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the six months ended June 30, 2015 and updates on its drug development programs. [More]
Urologists report success in treating bladder issues, pelvic pain through neuromodulation technique

Urologists report success in treating bladder issues, pelvic pain through neuromodulation technique

Millions of people suffer from bladder dysfunction, including about 30 million in the U.S. One in seven women experience chronic pelvic pain. These are not only health issues, but quality of life issues. [More]
Imprimis, Advanced Dosage sign license agreement for proprietary compounded ophthalmic formulations

Imprimis, Advanced Dosage sign license agreement for proprietary compounded ophthalmic formulations

Imprimis Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of proprietary compounded drug formulations, today announced that it has entered into a license agreement with Advanced Dosage Forms, Inc. to expand Imprimis' proprietary ophthalmic injectable and combination topical compounded formulations into Canada. Under the agreement, the licensee has the rights to formulate, market and sell these formulations across Canada. [More]
Increased radiation dose offers survival benefit for men with medium- and high-risk prostate cancer

Increased radiation dose offers survival benefit for men with medium- and high-risk prostate cancer

Increased radiation dose is associated with higher survival rates in men with medium- and high-risk prostate cancer, but not men with low-risk prostate cancer, according to a new study from Penn Medicine published this week in JAMA Oncology. Already-high survival rates for men with low-risk prostate cancer were unaffected by higher radiation dosages compared to lower radiation dosages. [More]
New study evaluates impact of U.S. Preventive Services Task Force Guidelines for PSA screening

New study evaluates impact of U.S. Preventive Services Task Force Guidelines for PSA screening

Current U.S. Preventive Services Task Force Guidelines for prostate screening may be impacting the detection of high-risk prostate cancer. [More]
Spotting the symptoms of advanced prostate cancer: an interview with Brian Tomlinson

Spotting the symptoms of advanced prostate cancer: an interview with Brian Tomlinson

The main symptoms of advanced prostate cancer can include (but are not limited to) difficulty walking or climbing steps, unexplained pain, troubled sleep and taking pain relievers daily. [More]
Expectant management remains underused for men with low-risk prostate cancer

Expectant management remains underused for men with low-risk prostate cancer

Monitoring men with very low- and low-risk prostate cancers using watchful waiting or active surveillance, called expectant management, is a useful approach for a large number of men with localized tumors and could spare them the debilitating side effects of aggressive treatments that are too often unnecessarily used in this patient population, a UCLA review of common practices in prostate cancer has found. [More]
Men referred for borderline testosterone levels have much higher rates of depression than general population

Men referred for borderline testosterone levels have much higher rates of depression than general population

Researchers at the George Washington University, led by Michael S. Irwig, M.D., found that men referred for tertiary care for borderline testosterone levels had much higher rates of depression and depressive symptoms than those of the general population. [More]
Loyola offers holistic approach to help couples manage their sexual health

Loyola offers holistic approach to help couples manage their sexual health

Cancer and cancer therapies are frequently associated with sexual dysfunction, yet this condition often goes untreated, according to specialists at Loyola Medicine's Sexual Wellness Clinic. [More]
Human breast milk bought online poses serious health risks

Human breast milk bought online poses serious health risks

The recent craze for human breast milk, which has become a lucrative online market, poses serious health risks, according to British experts. [More]
Study shows 28% decline in prostate cancer diagnoses following USPSTF recommendation against PSA testing

Study shows 28% decline in prostate cancer diagnoses following USPSTF recommendation against PSA testing

A new study led by Vanderbilt University Medical Center investigators found new diagnoses of prostate cancer in the U.S. declined 28 percent in the year following the draft recommendation from the United States Preventive Services Task Force against routine PSA screening for men. [More]
Low heart rate variability may place women at risk for sexual dysfunction

Low heart rate variability may place women at risk for sexual dysfunction

Chances are good that women with a low heart rate variability also suffer from sexual dysfunction. That's the finding from a study led by Amelia Stanton of The University of Texas at Austin in the US published in Springer's journal Applied Psychophysiology and Biofeedback. [More]
Men who use finasteride to treat benign prostate enlargement experience worsening ED

Men who use finasteride to treat benign prostate enlargement experience worsening ED

Men with benign prostate enlargement who used finasteride (also known as proscar and propecia) to treat their condition, experienced worsening erectile dysfunction (ED) that did not resolve with continued treatment. In addition, they experienced a reduction in their testosterone levels leading to hypogonadism (little to no production of sex hormones). [More]
Can-Fite BioPharma receives Notice of Allowance for patent covering manufacturing method of CF101 drug

Can-Fite BioPharma receives Notice of Allowance for patent covering manufacturing method of CF101 drug

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced the U.S. Patent & Trademark Office has issued a Notice of Allowance to the Company for an important manufacturing method patent for its drug candidate CF101. [More]
Can-Fite BioPharma reports Q1 2015 financial results, provides updates on drug development programs

Can-Fite BioPharma reports Q1 2015 financial results, provides updates on drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the three months ended March 31, 2015 and updates on its drug development programs. [More]
Endo Pharmaceuticals supports efforts to bring first ever treatment guidelines for Peyronie's Disease

Endo Pharmaceuticals supports efforts to bring first ever treatment guidelines for Peyronie's Disease

Endo Pharmaceuticals Inc., a subsidiary of Endo International plc, supports efforts to bring the medical community the first ever treatment guidelines for Peyronie's Disease (PD), a condition in which collagen plaque, or scar tissue, develops on the shaft of the penis, and may harden and reduce flexibility. [More]
Can-Fite receives EMA clearance to begin CF102 Phase II trial for treatment of HCC patients in Europe

Can-Fite receives EMA clearance to begin CF102 Phase II trial for treatment of HCC patients in Europe

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced it recently received clearance from the European Medicines Agency to commence dosing patients in Europe in its global Phase II trial for CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. [More]
Can-Fite announces favorable data from further analysis of CF101 Phase II/III study in patients with psoriasis

Can-Fite announces favorable data from further analysis of CF101 Phase II/III study in patients with psoriasis

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today favorable data from further analysis of its Phase II/III double-blind, placebo-controlled study designed to test the efficacy of CF101 in patients with moderate-to-severe plaque psoriasis. [More]
Can-Fite seeks EMA Orphan Drug Designation for CF102 in HCC

Can-Fite seeks EMA Orphan Drug Designation for CF102 in HCC

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has submitted an application to the European Medicines Agency for Orphan Drug Designation for its drug candidate CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. [More]
Non-vigorous walking may help prostate cancer survivors reduce damaging side effects

Non-vigorous walking may help prostate cancer survivors reduce damaging side effects

Walking at an easy pace for about three hours every week may be just enough physical activity to help prostate cancer survivors reduce damaging side effects of their treatment, according to a new Northwestern Medicine study. [More]
Advertisement
Advertisement